The amount consideration in the form of initial valuation of share subscription.

No definition available.

Name:	glpg_CollaborationAgreementConsiderationAsShareSubscription
Namespace Prefix:	glpg_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount of estimated significant financing component reflecting the time value of money on the estimated recognition period.

+ References

No definition available.

+ Details

Name:	glpg_CollaborationAgreementEstimatedSignificantFinancingComponentValue
Namespace Prefix:	glpg_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of revenue from milestone payments outstanding.

+ References

No definition available.

+ Details

Name:	glpg_MilestonesAchievedAmountOutstanding
Namespace Prefix:	glpg_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount of royalties outstanding.

+ References

No definition available.

+ Details

Name:	glpg_RoyaltiesAmountOutstanding
Namespace Prefix:	glpg_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount of royalties Received.

+ References

No definition available.

+ Details

Name:	glpg_RoyaltiesAmountReceived
Namespace Prefix:	glpg_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent summary of significant transaction.

+ References

No definition available.

+ Details

Name:	glpg_SummaryOfSignificantTransactionLineItems
Namespace Prefix:	glpg_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of the transaction price allocated to the performance obligations that are unsatisfied (or partially unsatisfied) as of the end of the reporting period before issuance of warrants liabilities.

+ References

No definition available.

+ Details

Name:	glpg_TransactionPriceBeforeDeductionOfWarrantsIssuance.
Namespace Prefix:	glpg_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount of Transaction Price Upfront Consideration.

+ References

No definition available.

+ Details

Name:	glpg_TransactionPriceUpfrontConsideration
Namespace Prefix:	glpg_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount of warrants issuance liabilities related to the entity's collaboration agreement with related parties

+ References

No definition available.

+ Details

Name:	glpg_WarrantsIssuanceLiabilities
Namespace Prefix:	glpg_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount of the transaction price allocated to the performance obligations that are unsatisfied (or partially unsatisfied) as of the end of the reporting period. The transaction price is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties (for example, some sales taxes). [Refer: Performance obligations [domain]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 15
-IssueDate 2025-01-01
-Paragraph 120
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_120_a&doctype=Standard
-URIDate 2025-03-27

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Note Effective 2027-01-01
-Name IFRS
-Number 19
-IssueDate 2025-01-01
-Paragraph 108
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_108_a&doctype=Standard
-URIDate 2025-03-27

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Note Effective 2027-01-01
-Name IFRS
-Number 19
-IssueDate 2025-01-01
-Paragraph 108
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_108_a&doctype=Standard
-URIDate 2025-03-27

+ Details

Name:	ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Details

Name:	ifrs-full_CounterpartiesAxis=glpg_GileadMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	glpg_IfrsScenarioAxis=glpg_OtherMovementsIn2024Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	glpg_IfrsScenarioAxis=glpg_OtherMovementsIn2025Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_ClassesOfLiabilitiesAxis=glpg_WarrantIssuanceLiabilityMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_ClassesOfLiabilitiesAxis=glpg_InitialWarrantBIssuanceLiabilityMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_ClassesOfLiabilitiesAxis=glpg_SubsequentWarrantBIssuanceLiabilityMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_PerformanceObligationsAxis=glpg_FilgotinibPerformanceObligationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	glpg_IfrsScenarioAxis=glpg_OriginalAgreementScenarioMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	glpg_IfrsScenarioAxis=glpg_FirstRevisedAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	glpg_IfrsScenarioAxis=glpg_SecondRevisedAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	glpg_IfrsScenarioAxis=glpg_AmendmentsRelatingToDiversityStudyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_PerformanceObligationsAxis=glpg_GileadCollaborationAgreementForZiritaxestatMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	glpg_IfrsTypeOfArrangementAxis=glpg_CollaborationAgreementForDrugDiscoveryPlatformMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Summary of significant transactions - Evolution of the total transaction price (Details) - Gilead - EUR (€)	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2015
Summary Of Significant Transaction [line items]
Upfront consideration	€ 4,018,016,000	€ 4,018,016,000	€ 4,018,016,000
Milestones achieved, balance	212,601,000	212,601,000	212,601,000
Royalties, balance	62,957,000	50,780,000	40,176,000
Impact initial valuation of share subscription	124,604,000	124,604,000	124,604,000
Transaction price before warrants issuances liabilities	4,418,178,000	4,406,001,000	4,395,397,000
Allocation to performance obligations	4,372,313,000	4,360,136,000	4,349,487,000
Other Movements In 2024 Member
Summary Of Significant Transaction [line items]
Royalties Amount Received		10,604,000
Transaction price before warrants issuances liabilities		10,604,000
Allocation to performance obligations		10,649,000
Other Movements In 2025 Member
Summary Of Significant Transaction [line items]
Royalties Amount Received	12,177,000
Transaction price before warrants issuances liabilities	12,177,000
Allocation to performance obligations	12,177,000
Warrant A
Summary Of Significant Transaction [line items]
Less : Warrants issuance liabilities	(43,311,000)	(43,311,000)	(43,311,000)
Initial Warrant B
Summary Of Significant Transaction [line items]
Less : Warrants issuance liabilities	(2,545,000)	(2,545,000)	(2,545,000)
Subsequent warrant B
Summary Of Significant Transaction [line items]
Less : Warrants issuance liabilities	(9,000)	(9,000)	(54,000)
Subsequent warrant B \| Other Movements In 2024 Member
Summary Of Significant Transaction [line items]
Less : Warrants issuance liabilities		45,000
Filgotinib Performance Obligation Member
Summary Of Significant Transaction [line items]
Upfront consideration					€ 160,000,000		€ 275,600,000
Allocation to performance obligations	1,404,425,000	1,392,248,000	1,381,644,000
Estimated significant financing component		39,300,000	39,800,000			€ 44,500,000
Filgotinib Performance Obligation Member \| Original Agreement
Summary Of Significant Transaction [line items]
Upfront consideration	4,000,000,000
Filgotinib Performance Obligation Member \| First Revised Agreement
Summary Of Significant Transaction [line items]
Upfront consideration						€ 3,600,000,000
Filgotinib Performance Obligation Member \| Second Revised Agreement
Summary Of Significant Transaction [line items]
Upfront consideration					€ 172,600,000
Filgotinib Performance Obligation Member \| Amendments Relating To The Diversity Study [member]
Summary Of Significant Transaction [line items]
Upfront consideration				€ 12,600,000
Filgotinib Performance Obligation Member \| Other Movements In 2024 Member
Summary Of Significant Transaction [line items]
Allocation to performance obligations		10,604,000
Filgotinib Performance Obligation Member \| Other Movements In 2025 Member
Summary Of Significant Transaction [line items]
Allocation to performance obligations	12,177,000
Gilead collaboration agreement for ziritaxestat
Summary Of Significant Transaction [line items]
Allocation to performance obligations	666,967,000	666,967,000	666,967,000
Collaboration agreement for drug discovery platform
Summary Of Significant Transaction [line items]
Allocation to performance obligations	€ 2,300,921,000	2,300,921,000	€ 2,300,876,000
Collaboration agreement for drug discovery platform \| Other Movements In 2024 Member
Summary Of Significant Transaction [line items]
Allocation to performance obligations		€ 45,000